Summary
Thermo Fisher Scientific Inc. reported a 5% decrease in revenue for the fiscal year ended December 30, 2023, primarily driven by a significant decline in COVID-19 related sales, which fell from $3.11 billion in 2022 to $0.33 billion in 2023. This reduction was partially offset by strong performance in the Analytical Instruments segment and the Laboratory Products and Biopharma Services segment, which saw revenue increases of 10% and 2% respectively on an organic basis. The company also executed significant restructuring actions, incurring $0.2 billion in charges to streamline operations, which are expected to yield $0.5 billion in annual cost savings. The company continues to focus on its three-pillar growth strategy: high-impact innovation, trusted partner status with customers, and an unparalleled commercial engine. Strategic acquisitions in 2023 included The Binding Site Group for specialty diagnostics and CorEvitas, LLC for real-world evidence solutions. Thermo Fisher also announced a proposed acquisition of Olink Holding AB for approximately $3.1 billion to expand its proteomics capabilities, subject to regulatory approvals and tender offer completion. Despite the revenue decline, the company maintained a strong free cash flow of $7.014 billion and returned capital to shareholders through share repurchases totaling $3.00 billion and dividend payments. The company ended the year with a robust cash position of $8.077 billion.
Financial Highlights
56 data points| Revenue | $42.86B |
| R&D Expenses | $1.34B |
| SG&A Expenses | $8.45B |
| Operating Expenses | $36.00B |
| Operating Income | $6.86B |
| Interest Expense | $1.38B |
| Net Income | $6.00B |
| EPS (Basic) | $15.52 |
| EPS (Diluted) | $15.45 |
| Shares Outstanding (Basic) | 386.00M |
| Shares Outstanding (Diluted) | 388.00M |
Key Highlights
- 1Total revenues decreased by 5% to $42.86 billion in 2023, largely due to a substantial drop in COVID-19 related revenue from $3.11 billion in 2022 to $0.33 billion in 2023.
- 2Life Sciences Solutions segment revenue declined by 26% organically, primarily reflecting the moderation in COVID-19 related demand.
- 3Analytical Instruments segment revenue grew by 10% organically, driven by strength in electron microscopy and chromatography/mass spectrometry.
- 4Laboratory Products and Biopharma Services segment revenue increased by 2% organically, supported by growth in clinical research and pharma services.
- 5The company repurchased $3.00 billion of its common stock in 2023 and announced a new authorization for up to $4.00 billion.
- 6Free cash flow remained strong at $7.014 billion in 2023.
- 7Thermo Fisher completed two strategic acquisitions in 2023: The Binding Site Group and CorEvitas, LLC.